VRDN · Insider trading · 13F holders · Congress trades
Viridian Therapeutics, Inc.\DE (VRDN)
Who is buying and selling VRDN: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 28
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $348K
- Congress trades, 12 months
- 0
VRDN at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 1 VRDN insider filed 1 sale worth $348K on SEC Form 4, and no open-market purchases.
- 28 13F filers hold VRDN among their 50 largest positions, worth $934.7M combined, including Behzad Aghazadeh and Julian and Felix Baker. The biggest bets by portfolio weight are Kynam Capital Management, LP (6.6%), Fairmount Funds Management LLC (6.2%) and Elmind Capital, LP (4.5%). In their latest 13Fs, 1 manager opened a new position and 15 added to one.
- No member of Congress has disclosed a trade in VRDN.
- VRDN last closed at $24.80 on Oct 29, 2026.
VRDN insider trading
Between Aug 1, 2026 and Oct 29, 2026, 1 VRDN insider filed 1 sale worth $348K on SEC Form 4, and no open-market purchases.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Aug 20, 2026 | Tousignant Jennifer | Chief Legal Officer | Sale | 14,212 | $24.50 | $348K | SEC |
Who owns VRDN? Hedge funds and superinvestors
28 13F filers hold VRDN among their 50 largest positions, worth $934.7M combined, including Behzad Aghazadeh and Julian and Felix Baker. The biggest bets by portfolio weight are Kynam Capital Management, LP (6.6%), Fairmount Funds Management LLC (6.2%) and Elmind Capital, LP (4.5%). In their latest 13Fs, 1 manager opened a new position and 15 added to one.
Superinvestors holding VRDN: Behzad Aghazadeh 0.4% · Julian and Felix Baker 0.2%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Bellevue Group AGInvestment manager | 2.6% | $123.7M | 6,731,909 | +0.1% shares | Q2 2026 |
| Paradigm Biocapital Advisors LPHedge fund | 2.3% | $123.5M | 6,723,788 | +113.5% shares | Q2 2026 |
| Kynam Capital Management, LPHedge fund | 6.6% | $118.6M | 6,453,877 | +175.6% shares | Q2 2026 |
| Fairmount Funds Management LLCHedge fund | 6.2% | $93.5M | 5,090,928 | +30.1% shares | Q2 2026 |
| Deep Track Capital, LPHedge fund | 1.0% | $66.0M | 3,592,740 | +157.7% shares | Q2 2026 |
| Venrock Adviser, LLCHedge fund | 1.8% | $59.8M | 3,257,917 | -16.1% shares | Q2 2026 |
| Behzad AghazadehHedge fund | 0.4% | $45.9M | 2,500,000 | +66.7% shares | Q2 2026 |
| Julian and Felix BakerHedge fund | 0.2% | $43.8M | 2,383,025 | +20.9% shares | Q2 2026 |
| Caligan Partners LPHedge fund | 1.9% | $40.3M | 2,193,981 | New | Q2 2026 |
| Novo Holdings A/sInvestment manager | 2.3% | $39.2M | 2,135,000 | +6.7% shares | Q2 2026 |
| Tang Capital Management LLCHedge fund | 1.5% | $32.9M | 1,792,626 | +0.0% shares | Q2 2026 |
| First Turn Management, LLCInstitutional asset manager | 3.3% | $30.7M | 1,670,000 | +83.2% shares | Q2 2026 |
| Parkman Healthcare Partners LLCHedge fund | 2.6% | $25.3M | 1,377,576 | +146.9% shares | Q2 2026 |
| Rice Hall James & Associates, LLCAsset manager | 1.1% | $21.6M | 1,175,906 | +30.9% shares | Q2 2026 |
| Elmind Capital, LPHedge fund | 4.5% | $18.1M | 984,931 | +84.1% shares | Q2 2026 |
| Eversept Partners, LPHedge fund | 0.8% | $15.3M | 831,142 | +16.5% shares | Q2 2026 |
| Ikarian Capital, LLCHedge fund | 1.3% | $7.8M | 425,000 | — | Q2 2026 |
| Yiheng Capital Management, L.P.Hedge fund | 3.1% | $7.4M | 400,464 | +91.9% shares | Q2 2026 |
| Blue Owl Capital Holdings LPHedge fund | 0.7% | $4.8M | 260,000 | — | Q2 2026 |
| Knott David M JrInvestment manager | 1.8% | $3.3M | 181,000 | +0.0% shares | Q2 2026 |
| Privium Fund Management B.V.Asset manager | 0.6% | $3.2M | 173,516 | +0.0% shares | Q2 2026 |
| HighVista Strategies LLCHedge fund | 0.7% | $2.9M | 159,885 | +19.1% shares | Q2 2026 |
| KVP Capital Advisors, LPHedge fund | 1.7% | $2.3M | 125,000 | +0.0% shares | Q2 2026 |
| Diadema Partners LPHedge fund | 0.7% | $1.8M | 100,000 | — | Q2 2026 |
| Merck & Co., Inc.Corporation | 0.3% | $1.7M | 93,414 | +0.0% shares | Q2 2026 |
| Verdad Advisers, LPAsset manager | 0.7% | $711K | 38,722 | +24.2% shares | Q2 2026 |
| Bayforest Capital LtdHedge fund | 0.3% | $363K | 19,775 | — | Q2 2026 |
| Velan Capital Investment Management LPHedge fund | 0.1% | $184K | 10,000 | -89.0% shares | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 28). Screen VRDN in the grand portfolio →
VRDN stock trades by members of Congress
No member of Congress has disclosed a trade in VRDN.
Analysis mentioning VRDN
Posts from the blog that cover Viridian Therapeutics, Inc.\DE, newest first.
VRDN questions and answers
Are insiders buying VRDN stock?
Between Aug 1, 2026 and Oct 29, 2026, 1 VRDN insider filed 1 sale worth $348K on SEC Form 4, and no open-market purchases.
Which hedge funds own VRDN?
28 13F filers hold VRDN among their 50 largest positions, worth $934.7M combined, including Behzad Aghazadeh and Julian and Felix Baker. The biggest bets by portfolio weight are Kynam Capital Management, LP (6.6%), Fairmount Funds Management LLC (6.2%) and Elmind Capital, LP (4.5%). In their latest 13Fs, 1 manager opened a new position and 15 added to one.
Has Congress traded VRDN?
No member of Congress has disclosed a trade in VRDN.
Who is the largest holder of VRDN?
Among 13F filers, Bellevue Group AG reports the largest VRDN position, $123.7M (6,731,909 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Kynam Capital Management, LP's: 6.6% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.